

**Critical Limb Ischemia Volume II**  
**Table of Contents**

INTRODUCTION .....	10
PURPOSE .....	10
METHODS .....	10
Diabetes Method .....	10
PERIPHERAL ARTERIAL DISEASE (PAD) .....	11
INTERMITTENT CLAUDICATION .....	11
An Uncommon Symptom .....	11
LIMB ISCHEMIA .....	11
Acute Limb Ischemia (ALI)—Leg Attack.....	12
Location .....	12
Occlusion Classification System.....	12
Critical Limb Ischemia (CLI) .....	13
Symptoms .....	13
Risk Factors .....	13
A Bilateral Disease .....	13
Multilevel Disease .....	14
Serious Comorbidities.....	14
DIABETES .....	15
Diabetes Defined.....	15
A Note on Diabetes Terminology.....	15
Prediabetes Defined .....	15
Risk Factors .....	16
Mortality .....	16
DIABETES AND PERIPHERAL ARTERIAL DISEASE .....	16
PAD Highly Prevalent in Diabetics .....	16
Diabetics Have Increased Risk for Developing PAD .....	16
Other Factors That Increase Risk of PAD in Diabetics .....	16
Eurodiale—High Prevalence of PAD in Patients with Foot Ulcers .....	17
DIABETES AND CRITICAL LIMB ISCHEMIA.....	17
Higher Risk of CLI and More Severe Disease.....	17
CLI Develops Suddenly.....	17
Diabetes Increases the Risk of Amputation.....	18
Risk of Amputation Related to Severity of Diabetes.....	18
Higher Mortality .....	18
Additional Risk Factors Increase Severity.....	18
Diabetes and Smoking—A Deadly Combination.....	19
DIABETES AND PREDIABETES—AN EPIDEMIC .....	19
Diabetes Prevalence Increases with Age .....	20
DIABETES METHOD .....	20
Glucose Status by Age and Sex .....	21
Estimation Procedure Summarized.....	21
Peripheral Arterial Disease .....	21
Critical Limb Ischemia .....	22

Diabetes Prevalence Held Constant .....	22
Western Europe.....	23
Definition .....	23
Region and Country Specific Population Projections.....	23
WESTERN EUROPE—MARKET OVERVIEW .....	23
Regional Prevalence of PAD .....	23
Regional Prevalence of Critical Limb Ischemia .....	23
Largest Western European Markets—Germany, Italy, Spain, U.K. and France .....	23
GERMANY—PREVALENCE OF PAD AND CLI .....	25
GERMANY—PREVALENCE OF PAD AND CLI .....	25
Estimation Methods and Assumptions .....	25
Population Age 65 and Older.....	26
Glucose Status.....	26
PAD Prevalence by Glucose Status .....	26
Critical Limb Ischemia Prevalence .....	27
Population 45-64.....	27
Glucose Status.....	27
PAD Prevalence by Glucose Status .....	28
Critical Limb Ischemia Prevalence .....	28
Population 25-44.....	29
Glucose Status.....	29
PAD Prevalence by Glucose Status .....	29
GERMAN POPULATION-BASED RESEARCH.....	29
German Epidemiological Trial on Ankle Brachial Index (getABI).....	29
Diabetes.....	30
MONICA Augsburg Survey .....	31
Heinz Nixdorf Recall Study.....	31
Critical Limb Ischemia .....	32
KORA Survey .....	32
ITALY—PREVALENCE OF PAD AND CLI .....	34
Estimation Methods and Assumptions .....	34
Population Age 60 and Older.....	35
Glucose Status by Age.....	35
PAD Prevalence by Glucose Status .....	35
Critical Limb Ischemia by Glucose Category.....	36
Population Ages 40-59.....	36
Glucose Status.....	36
PAD Prevalence by Glucose Status .....	37
Critical Limb Ischemia by Glucose Category.....	37
Population Age 20-39 .....	38
Glucose Status.....	38
PAD Prevalence by Glucose Status .....	38
SPAIN—PREVALENCE OF PAD AND CLI.....	39
Estimation Methods and Assumptions .....	39
Population 65 and Older .....	40
Glucose Status by Age .....	40

PAD Prevalence by Glucose Status .....	40
Critical Limb Ischemia by Glucose Category .....	42
Population 45-64 .....	42
Glucose Status .....	42
PAD Prevalence by Glucose Status .....	43
Critical Limb Ischemia by Glucose Category .....	43
Population 25-44 .....	43
Glucose Status .....	44
PAD Prevalence by Glucose Status .....	44
UNITED KINGDOM—PREVALENCE OF PAD AND CLI .....	45
Estimation Methods and Assumptions .....	45
Population Age 65 and Older .....	46
Glucose Status by Age .....	46
PAD Prevalence by Glucose Status .....	46
Critical Limb Ischemia by Glucose Category .....	47
Population 45-64 .....	47
PAD Prevalence by Glucose Status .....	48
Critical Limb Ischemia by Glucose Category .....	49
Population Age 35-44 .....	49
Glucose Status .....	49
PAD Prevalence by Glucose Status .....	49
OXVASC—Population-Based Incidence by Age and Sex .....	50
Description .....	50
Incidence by Age and Sex .....	50
Limitations .....	51
FRANCE—PREVALENCE OF PAD AND CLI .....	52
Estimation Methods and Assumptions .....	52
Population Age 65 and Older .....	53
PAD Prevalence by Glucose Status .....	53
Critical Limb Ischemia .....	54
Population 45-64 .....	55
Glucose Status .....	55
PAD Prevalence by Glucose Status .....	55
Critical Limb Ischemia .....	56
Population Age 30-44 .....	56
Glucose Status .....	56
PAD Prevalence by Glucose Status .....	56
THE NETHERLANDS—PREVALENCE OF PAD AND CLI .....	57
Estimation Methods and Assumptions .....	57
Population 60 and Older .....	58
Glucose Status by Age .....	58
PAD Prevalence by Glucose Status .....	58
Critical Limb Ischemia by Glucose Category .....	59
Population 50-59 .....	59
Glucose Status .....	60
PAD Prevalence by Glucose Status .....	60

PAD Prevalence in the Netherlands Population Ages 50 and Older .....	61
Critical Limb Ischemia by Glucose Category .....	61
Population 30-49 .....	62
Glucose Status .....	62
PAD Prevalence by Glucose Status .....	62
GREECE—PREVALENCE OF PAD AND CLI .....	63
Estimation Methods and Assumptions .....	63
Population Age 60 and Older .....	64
Glucose Status by Age .....	64
PAD Prevalence by Glucose Status .....	65
Critical Limb Ischemia by Glucose Category .....	65
Population Ages 40-59 .....	65
Glucose Status .....	66
PAD Prevalence by Glucose Status .....	66
Critical Limb Ischemia by Glucose Category .....	66
Population Age 30-39 .....	67
Glucose Status .....	67
PAD Prevalence by Glucose Status .....	67
SWEDEN—PREVALENCE OF PAD AND CLI .....	68
Estimation Methods and Assumptions .....	68
Population 65 and Older .....	69
Glucose Status .....	69
PAD Prevalence by Glucose Status .....	69
Critical Limb Ischemia by Glucose Category .....	70
Population 45-64 .....	71
Glucose Status .....	71
PAD Prevalence by Glucose Status .....	71
Critical Limb Ischemia by Glucose Category .....	71
Population 25-44 .....	72
Glucose Status .....	72
PAD Prevalence by Glucose Status .....	72
AUSTRIA—PREVALENCE OF PAD AND CLI .....	73
Estimation Methods and Assumptions .....	73
Population 65 and Older .....	74
Glucose Status .....	74
PAD Prevalence by Glucose Status .....	74
Critical Limb Ischemia by Glucose Category .....	75
Population 45-64 .....	75
Glucose Status .....	75
PAD Prevalence by Glucose Status .....	75
Critical Limb Ischemia by Glucose Category .....	76
Population 25-44 .....	76
Glucose Status .....	76
PAD Prevalence by Glucose Status .....	76
SWITZERLAND—PREVALENCE OF PAD AND CLI .....	77
Estimation Methods and Assumptions .....	77

Population 65 and Older .....	78
Glucose Status.....	78
PAD Prevalence by Glucose Status .....	78
Critical Limb Ischemia by Glucose Category.....	79
Population 45-64.....	80
Glucose Status.....	80
PAD Prevalence by Glucose Status .....	80
Critical Limb Ischemia by Glucose Category.....	80
Population 25-44.....	81
Glucose Status.....	81
PAD Prevalence by Glucose Status .....	81
BELGIUM—PREVALENCE OF PAD AND CLI .....	82
Estimation Methods and Assumptions .....	82
Population 65 and Older .....	83
Glucose Status.....	83
PAD Prevalence by Glucose Status .....	83
Critical Limb Ischemia by Glucose Category.....	84
Population 45-64.....	84
Glucose Status.....	84
PAD Prevalence by Glucose Status .....	85
Critical Limb Ischemia by Glucose Category.....	85
Population 25-44.....	86
Glucose Status.....	86
PAD Prevalence by Glucose Status .....	86
PORTUGAL—PREVALENCE OF PAD AND CLI .....	87
Estimation Methods and Assumptions .....	87
Population 65 and Older .....	88
Glucose Status.....	88
PAD Prevalence by Glucose Status .....	88
Critical Limb Ischemia by Glucose Category.....	89
Population 45-64.....	89
Glucose Status.....	89
PAD Prevalence by Glucose Status .....	89
Critical Limb Ischemia by Glucose Category.....	90
Population 25-44.....	90
Glucose Status.....	90
PAD Prevalence by Glucose Status .....	90
FINLAND—PREVALENCE OF PAD AND CLI.....	91
Estimation Methods and Assumptions .....	91
Population 65 and Older .....	92
Glucose Status.....	92
PAD Prevalence by Glucose Status .....	92
Critical Limb Ischemia by Glucose Category.....	93
Population 45-64.....	94
Glucose Status.....	94
PAD Prevalence by Glucose Status .....	94

Critical Limb Ischemia by Glucose Category.....	94
Population 25-44.....	95
Glucose Status.....	95
PAD Prevalence by Glucose Status.....	95
DENMARK—PREVALENCE OF PAD AND CLI.....	96
Estimation Methods and Assumptions.....	96
Population 65 and Older.....	97
Glucose Status.....	97
PAD Prevalence by Glucose Status.....	97
Critical Limb Ischemia by Glucose Category.....	98
Population 45-64.....	98
Glucose Status.....	98
PAD Prevalence by Glucose Status.....	99
Critical Limb Ischemia by Glucose Category.....	99
Population 25-44.....	99
Glucose Status.....	99
PAD Prevalence by Glucose Status.....	100
NORWAY—PREVALENCE OF PAD AND CLI.....	101
Estimation Methods and Assumptions.....	102
Population 60 and Older.....	102
Glucose Status.....	102
PAD Prevalence by Glucose Status.....	102
Critical Limb Ischemia by Glucose Category.....	103
Population 40-59.....	104
Glucose Status.....	104
PAD Prevalence by Glucose Status.....	104
Critical Limb Ischemia by Glucose Category.....	104
Population 30-39.....	105
Glucose Status.....	105
PAD Prevalence by Glucose Status.....	105
WESTERN EUROPE—PAD AND CLI PREVALENCE COMPARED WITH THE UNITED STATES.....	106
CRITICAL LIMB ISCHEMIA MARKET OVERVIEW 2000-2020.....	106
Estimated Number of Patients and Procedures According to the Ideal Treatment Pathway.....	106
Actual CLI Treatment Pathway Often Differs from the Ideal.....	108
CURRENT ENDOVASCULAR MARKET.....	109
Peripheral Arterial Disease Market.....	109
Critical Limb Ischemia Market.....	109
CRITICAL LIMB ISCHEMIA— POTENTIAL REVASCULARIZATION MARKET.....	110
ENDOVASCULAR MARKET.....	111
Number of Limbs Requiring Endovascular Therapy.....	111
ENDOVASCULAR MARKET—DOLLAR VALUE.....	112
Assumptions.....	113
Endovascular Therapy Mix.....	113

Stenting .....	113
Prices .....	113
MARKET IMPACT OF NEW PERCUTANEOUS TECHNOLOGY .....	114
STENT MARKET .....	115
COMPARISON OF CURRENT AND POTENTIAL ENDOVASCULAR MARKETS FOR CRITICAL LIMB ISCHEMIA .....	117
SURGICAL BYPASS MARKET .....	118
MARKET IMPACT OF CONTINUED ENDOVASCULAR SHARE GAINS .....	119
CHRONIC TOTAL OCCLUSIONS .....	120
PHARMACEUTICAL THERAPIES .....	121
RISK-FACTOR MODIFICATION THERAPIES .....	122
Antihypertensives .....	122
Antilipids .....	123
Antiplatelets .....	124
NO REVASCULARIZATION PATIENTS .....	125
DIAGNOSTIC MARKET .....	125
ADJUNCT THERAPY IN REVASCULARIZED PATIENTS .....	126
Bypass Patients .....	126
Endovascular Patients .....	126
THROMBOLYTICS .....	126
MECHANICAL THROMBECTOMY .....	126
APPENDIX A .....	128
Countries Included in Western Europe .....	128
APPENDIX B .....	129
PAD Definitions and Diagnostic Methods .....	129
Affect Prevalence .....	129
Limitations of ABI < 0.90 .....	129
Abnormally High ABI May Also Indicate Disease .....	129
REFERENCES .....	131
INDEX OF TABLES .....	148
INDEX OF FIGURES .....	155
DISCLOSURE STATEMENT .....	156
Stock Ownership .....	156
CONTACT INFORMATION .....	157